Home › Left Ventricular Dysfunction › New York › The Bronx
Left Ventricular Dysfunction clinical trials in The Bronx, NY
3 studies for Left Ventricular Dysfunction are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
RecruitingPhase 2/3
- The Children's Hospital at Montefiore ( Site 0030), The Bronx
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingPhase 3
- The Children's Hospital at Montefiore - Cardiology, The Bronx
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingPhase 3
- The Children's Hospital at Montefiore - Cardiology, The Bronx
Left Ventricular Dysfunction trials in other cities
- Cleveland, OH4 studies
- New York City, NY4 studies
- Boston, MA3 studies
- Philadelphia, PA3 studies
- Pittsburgh, PA3 studies
- Aurora, CO3 studies
- Atlanta, GA3 studies
- Ann Arbor, MI3 studies
- St. Louis, MO3 studies
- Dallas, TX3 studies
- Houston, TX3 studies
- Cincinnati, OH3 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer13 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Prostate Cancer11 studies
- Heart Failure11 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
- Asthma9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.